Treatment of localized prostate cancer: Choosing the best alternative

Postgraduate Medicine

Volumn 100, Issue 3, 1996, Pages 105-120

  Williams, Tim R ^a   Love, Neil ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CANCER RADIOTHERAPY; CONFERENCE PAPER; HUMAN; LIFE EXPECTANCY; MALE; MEDICAL DECISION MAKING; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0029786183     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1996.09.72     Document Type: Conference Paper

References (25)

1. Bureau of the Census. The American almanac: statistical abstract of the United States. 115th ed. Austin, Tex: The Reference Press, 1996
2. Cantrell BB, DeKlerk DP, Eggleston JC, et al. Pathological factors that influence prognosis in stage A prostate cancer: the influence of extent versus grade. J Urol 1981;125(4):516-9
3. Johansson JE, Adami HO, Andersson SO, et al. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992; 267(16):2191-6
4. Adolfsson J, Carstensen J, Lowhagen T. Deferred treatment in clinically localised prostatic carcinoma. Br J Urol 1991;69(2):183-7
5. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330(4):242-8
6. Albertson PC, Fryback DG, Storer BE, et al. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995;274(8):626-31
7. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152(5 Pt 2):1837-42
8. Ohori M, Goad JR, Wheeler TM, et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152(5 Pt 2):1843-9
9. Partin AW, Pearson JD, Landis PK, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43(5):649-59
10. Trapasso JG, deKernion JB, Smith RB, et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152(5 Pt 2):1821-5
11. Zincke H, Oesterling JE, Blute ML, et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152(5 Pt 2):1850-7
12. Corn BW, Hanks GE. Therapeutic options for clinically localized carcinoma of the prostate. Semin Rad Oncol 1993;3(3):187-97
13. Fowler FJ Jr, Barry MJ, Lu-Yao G, et al. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990. Urology 1993;42(6):622-9
14. Hautmann RE, Sauter TW, Wenderoth UK. Radical retropubic prostatectomy: morbidity and urinary continence in 418 consecutive cases. Urology 1994;43(2 Suppl):47-51
15. Murphy GP, Mettlin C, Menck H, et al. National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol 1994; 152(5 Pt 2):1817-9
16. Steiner MS, Morton RA, Walsh PC. Impact of anatomical radical prostatectomy on urinary continence. J Urol 1991;145(3):512-4; discussion 514-5
17. Kaplan ID, Cox RS, Bagshaw MA. Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup. J Urol 1993; 149(3):519-22
18. Leibel SA, Zelefsky MJ, Kutcher GJ, et al. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: interim report of a phase I dose-escalation study. J Urol 1994;152(5 Pt 2):1792-8
19. Zagars GK. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol 1994;152(5 Pt 2): 1786-91
20. Zietman AL, Coen JJ, Shipley WU, et al. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994; 151(3):640-5
21. Blasko JC, Grimm PD, Rade H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Rad Oncol 1993;3(4):240-9
22. Labrie F, Dupont A, Cusan L, et al. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med (Canada) 1993; 16(6):499-509
23. Stock RG. Locoregional therapies for early-stage prostate cancer. Oncology (Huntingt) 1995;9(9):803-16
24. Onik GM, Cohen JK, Reyes GD, et al. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer 1993;72(4):1291-9
25. Steinfeld AD. Questions regarding the treatment of localized prostate cancer. Radiology 1992;184(3):593-8